» Articles » PMID: 36899943

Perfusion Air Culture of Precision-Cut Tumor Slices: An Ex Vivo System to Evaluate Individual Drug Response Under Controlled Culture Conditions

Abstract

Precision-cut tumor slices (PCTS) maintain tissue heterogeneity concerning different cell types and preserve the tumor microenvironment (TME). Typically, PCTS are cultured statically on a filter support at an air-liquid interface, which gives rise to intra-slice gradients during culture. To overcome this problem, we developed a perfusion air culture (PAC) system that can provide a continuous and controlled oxygen medium, and drug supply. This makes it an adaptable ex vivo system for evaluating drug responses in a tissue-specific microenvironment. PCTS from mouse xenografts (MCF-7, H1437) and primary human ovarian tumors (primary OV) cultured in the PAC system maintained the morphology, proliferation, and TME for more than 7 days, and no intra-slice gradients were observed. Cultured PCTS were analyzed for DNA damage, apoptosis, and transcriptional biomarkers for the cellular stress response. For the primary OV slices, cisplatin treatment induced a diverse increase in the cleavage of caspase-3 and PD-L1 expression, indicating a heterogeneous response to drug treatment between patients. Immune cells were preserved throughout the culturing period, indicating that immune therapy can be analyzed. The novel PAC system is suitable for assessing individual drug responses and can thus be used as a preclinical model to predict in vivo therapy responses.

Citing Articles

Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy.

Hughes D, Evans A, Go S, Eyres M, Pan L, Mukherjee S Sci Adv. 2024; 10(27):eadm9071.

PMID: 38968363 PMC: 11225792. DOI: 10.1126/sciadv.adm9071.


Complex in vitro Model: A Transformative Model in Drug Development and Precision Medicine.

Wang L, Hu D, Xu J, Hu J, Wang Y Clin Transl Sci. 2023; .

PMID: 38062923 PMC: 10828975. DOI: 10.1111/cts.13695.


Breast Cancer Tissue Explants: An Approach to Develop Personalized Therapy in Public Health Services.

Carranza-Rosales P, Valencia-Mercado D, Esquivel-Hernandez O, Gonzalez-Geroniz M, Banuelos-Garcia J, Castruita-Avila A J Pers Med. 2023; 13(10).

PMID: 37888132 PMC: 10608341. DOI: 10.3390/jpm13101521.

References
1.
Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

2.
Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

3.
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M . Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6:6169. PMC: 4351621. DOI: 10.1038/ncomms7169. View

4.
Hickman J, Graeser R, De Hoogt R, Vidic S, Brito C, Gutekunst M . Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J. 2014; 9(9):1115-28. DOI: 10.1002/biot.201300492. View

5.
Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G . Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett. 2019; 464:5-14. DOI: 10.1016/j.canlet.2019.08.005. View